Garth Powis named as NAI Fellow

December 13, 2016

La Jolla, Calif., Dec. 13, 2016 - Garth Powis, professor and director of Sanford Burnham Prebys Medical Discovery Institute's (SBP) NCI-designated Cancer Center, has been named a Fellow of the National Academy of Inventors (NAI).

Election to NAI Fellow status is a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.

Powis is the Jeanne and Gary Herberger Leadership Chair in Cancer Research at the Institute's Cancer Research Center in La Jolla, CA. Previously he was Professor and Chair, Department of Experimental Therapeutics, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, TX. Powis received his B.Sc. in Biochemistry and Pharmacology from the University of Birmingham, and his D.Phil. in Biochemistry and Pharmacology from Oxford University in the U.K. Powis has been a pioneer in the discovery and translation of novel cancer targets and their small molecule inhibitors as potential cancer therapies. His current research focuses on mechanisms that solid tumors use to adapt and survive in hypoxic environments, escape cell death, form new blood vessels and metastasize.

Powis is the author of over 350 peer-reviewed publications and 15 patents, supporting first in class anti-cancer agents, three of which are in clinical trials. They include: PX-12, a thioredoxin inhibitor; PX-866, a phosphatidylinositol-3-kinase inhibitor; and PX-478, an inhibitor of hypoxia inducible factor-1 (HIF-1). He is co-founder of two start-up companies, Prolx Pharmaceuticals, which was acquired by Biomira (now Cascadia), and Phusis Therapeutics.

"Dr. Powis exemplifies the innovative and entrepreneurial spirit of faculty and researchers at SBP," said Kristiina Vuori, M.D., Ph.D., president of SBP. "His contributions to cancer research have changed the way cancer treatment has evolved, from systemic chemotherapy to personalized molecularly targeted therapy. On behalf of SBP, I would like to congratulate Dr. Powis for the distinguished honor of being elected as an NAI Fellow."

The 175 distinguished academic inventors named today bring the total number of NAI Fellows to 757, representing 229 research universities and governmental and non-profit research institutes. The 2016 Fellows are named inventors on 5,437 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 26,000. These academic luminaries have made a significant impact on the economy through innovative discoveries, creating startup companies, and enhancing the culture of academic invention.

Included among all NAI Fellows are more than 94 presidents and senior leaders of research universities and non-profit research institutes; 376 members of the three branches of the National Academy of Sciences; 28 inductees of the National Inventors Hall of Fame; 45 recipients of the U.S. National Medal of Technology and Innovation and U.S. National Medal of Science; 28 Nobel Laureates, 215 AAAS Fellows; 132 IEEE Fellows; and 116 Fellows of the American Academy of Arts & Sciences, among other awards and distinctions.

Powis will be inducted on April 6, 2017, as part of the Sixth Annual Conference of the National Academy of Inventors at the John F. Kennedy Presidential Library & Museum in Boston, MA. U.S. Commissioner for Patents, Andrew H. Hirshfeld will provide the keynote address for the induction ceremony. In honor of their outstanding accomplishments, Fellows will be presented with a special trophy, medal, and rosette pin.
-end-
About SBP

Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children's diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its world-class NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs about 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

Sanford-Burnham Prebys Medical Discovery Institute

Related Cancer Research Articles from Brightsurf:

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.

UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.

Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.

Read More: Cancer Research News and Cancer Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.